Kimberley Joanne Hatfield

List of Publications by Year
in descending order

24 papers	906 citations	471509 17 h-index	610901 24 g-index
24 all docs	24 docs citations	24 times ranked	1184 citing authors

#	Article	IF	Citations
1	Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules, 2022, 12, 492.	4.0	1
2	MicroRNA serum profiles and chronic graft-versus-host disease. Blood Advances, 2022, 6, 5295-5306.	5.2	6
3	Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity. Cells, 2020, 9, 1155.	4.1	25
4	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. International Journal of Molecular Sciences, 2020, 21, 2907.	4.1	158
5	Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells, 2019, 8, 1229.	4.1	18
6	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy, 2019, 4, 20.	17.1	46
7	The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. Cytotherapy, 2018, 20, 740-754.	0.7	5
8	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. Cancers, 2018, 10, 332.	3.7	24
9	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. International Journal of Molecular Sciences, 2018, 19, 382.	4.1	20
10	Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors. Metabolomics, 2017, 13, 2.	3.0	19
11	Targeting of cell metabolism in human acute myeloid leukemia â€“ more than targeting of isocitrate dehydrogenase mutations and <scp>PI</scp>3K/<scp>AKT</scp>/<scp>mTOR</scp> signaling?. European Journal of Haematology, 2016, 96, 211-221.	2.2	16
12	Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Cytotherapy, 2016, 18, 172-185.	0.7	49
13	The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. Metabolomics, 2016, 12, 12.	3.0	34
14	Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome. Disease Markers, 2015, 2015, 1-13.	1.3	15
15	The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Research, 2015, 15, 530-541.	0.7	51
16	Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation. Journal of Transplantation, 2014, 2014, 1-9.	0.5	15
17	Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget, 2013, 4, 830-843.	1.8	43
18	Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology, 2011, 16, 351-356.	1.5	38

#	Article	IF	Citations
19	Hypoxia increases HIF-1Î± expression andÂconstitutive cytokine release byÂprimary human acute myeloid leukaemia cells. European Cytokine Network, 2010, 21, 154-64.	2.0	36
20	Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology, 2009, 144, 53-68.	2.5	61
21	Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. International Journal of Oncology, 2007, , .	3.3	17
22	The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology, 2007, 136, 814-828.	2.5	115
23	Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. International Journal of Oncology, 2007, 31, 1529-38.	3.3	19
24	Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. International Journal of Cancer, 2006, 119, 2313-2321.	5.1	75